Priv.- Doz. Dr. med. Lukas Martin, MHBA

Priv.- Doz. Dr. med. Lukas Martin, MHBA has an extensive work experience in medical research and academia. In 2019, they became Co-Founder and Chief Executive Officer of Clinomic. From 2014 to 2019, they worked at University Hospital Aachen, where they held roles such as Consultant Intensive Care Medicine, Group Lead (Translational Intensive Care Medicine), Fellowship in Anaesthesia, Critical Care Medicine, Emergency Medicine, and Postdoctoral Research Scientist. From 2016 to 2019, they were an Honorary Senior Visiting Lecturer, Honorary Visiting Lecturer, and Visiting Research Fellow at Queen Mary University of London. In 2019, they became a Member of Development and Strategy Board at William Harvey Research Ltd. In 2018, they joined the Editorial Board of Frontiers in Immunology, Inflammation and SHOCK of Wolters Kluwer International Group.

Priv.- Doz. Dr. med. Lukas Martin, MHBA completed their Doctor of Medicine (MD) from RWTH Aachen University between 2006 and 2013. Priv.- Doz. Dr. med. Lukas then pursued their Promotion Dr. med. (MD Thesis) from the same university in the Department of Intensive Care and Intermediate Care, which they completed between 2010 and 2013. In 2016, they obtained their Master of Health Business Administration from FAU Erlangen-Nürnberg in the field of Health Business Administration. Finally, they earned their Habilitation from RWTH Aachen University in Anästhesiologie und Intensivmedizin between 2014 and 2018.